Sunmax Biotechnology Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.111x

Sunmax Biotechnology Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has a cash flow conversion efficiency ratio of 0.111x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$160.84 Million ≈ $5.07 Million USD) by net assets (NT$1.44 Billion ≈ $45.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sunmax Biotechnology Co Ltd (2015–2024)

Cash flow conversion efficiency of Sunmax Biotechnology Co Ltd from 2015 to 2024. This chart illustrates how Sunmax Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Sunmax Biotechnology Co Ltd stock price today for real-time trading data and today's change.

Sunmax Biotechnology Co Ltd Cash Flow Conversion Ratio Explained

Sunmax Biotechnology Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sunmax Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Sunmax Biotechnology Co Ltd for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Anhui Korrun Co Ltd
SHE:300577
0.086x
Suqian Unitech Corp. Ltd. Cl A
SHG:603065
N/A
Shanghai Yct Electronics Group Co.Ltd
SHE:301099
N/A
Sapphire Foods India Limited
NSE:SAPPHIRE
0.152x
Hainan Shennong Technology Co Ltd
SHE:300189
0.008x
Beijing Utour International Travel Service Co Ltd
SHE:002707
0.167x
Charter Hall Social Infrastructure REIT
AU:CQE
0.011x
CERES POWER HLDGS
F:CFJ
-0.016x

Annual Cash Flow Conversion Efficiency for Sunmax Biotechnology Co Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of Sunmax Biotechnology Co Ltd from 2015 to 2024. Review Sunmax Biotechnology Co Ltd (4728) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 NT$1.51 Billion
≈ $47.66 Million
NT$397.37 Million
≈ $12.52 Million
0.263x -55.86%
2023-12-31 NT$1.43 Billion
≈ $44.93 Million
NT$848.56 Million
≈ $26.73 Million
0.595x +129.93%
2022-12-31 NT$1.33 Billion
≈ $41.75 Million
NT$342.97 Million
≈ $10.81 Million
0.259x +8.88%
2021-12-31 NT$1.02 Billion
≈ $32.25 Million
NT$243.28 Million
≈ $7.66 Million
0.238x -45.41%
2020-12-31 NT$888.84 Million
≈ $28.00 Million
NT$386.97 Million
≈ $12.19 Million
0.435x +1.78%
2019-12-31 NT$676.83 Million
≈ $21.32 Million
NT$289.51 Million
≈ $9.12 Million
0.428x +174.90%
2018-12-31 NT$648.01 Million
≈ $20.42 Million
NT$100.83 Million
≈ $3.18 Million
0.156x +140.26%
2017-12-31 NT$572.70 Million
≈ $18.04 Million
NT$37.09 Million
≈ $1.17 Million
0.065x +116.86%
2016-12-31 NT$555.29 Million
≈ $17.49 Million
NT$16.58 Million
≈ $522.46K
0.030x +172.98%
2015-12-31 NT$558.24 Million
≈ $17.59 Million
NT$-22.84 Million
≈ $-719.74K
-0.041x --

About Sunmax Biotechnology Co Ltd

TWO:4728 Taiwan Biotechnology
Market Cap
$680.35 Million
NT$21.59 Billion TWD
Market Cap Rank
#10019 Global
#304 in Taiwan
Share Price
NT$396.50
Change (1 day)
+4.62%
52-Week Range
NT$373.00 - NT$409.00
All Time High
NT$494.50
About

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.